Despite our growing understanding of the genomic landscape of diffuse pleural mesotheliomas (DPM), there has been limited success in targeted therapeutic strategies for the disease. This review summarizes attempts to develop targeted therapies in DPM, focusing on the following targets being clinically explored in recent and ongoing clinical trials: vascular endothelial growth factor, mesothelin, BRCA1-associated protein 1, Wilms tumor 1 protein, NF2/YAP/TAZ, CDKN2, methylthioadenosine phosphorylase, v-domain Ig suppressor T-cell activation, and argininosuccinate synthetase 1. Although preclinical data for these targets are promising, few have efficaciously translated to benefit our patients. Future efforts should seek to expand the availability of preclinical models that faithfully recapitulate DPM biology, develop clinically relevant biomarkers, and refine patient selection criteria for clinical trials.
Keyphrases
- clinical trial
- vascular endothelial growth factor
- end stage renal disease
- newly diagnosed
- ejection fraction
- chronic kidney disease
- cancer therapy
- low grade
- signaling pathway
- peritoneal dialysis
- cell therapy
- prognostic factors
- phase ii
- randomized controlled trial
- case report
- machine learning
- big data
- pi k akt
- patient reported outcomes
- cell proliferation
- small molecule
- patient reported